

**DESCRIPTION**

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human VHL in direct ELISA.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 1066409
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant human VHL Asn150-Asp213 Accession # P40337
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.


**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Immunohistochemistry</b>	5-15 µg/mL	Immersion fixed paraffin-embedded sections of Human Kidney

**DATA**

**Immunohistochemistry**



**Detection of VHL in Human Kidney.** VHL was detected in immersion fixed paraffin-embedded sections of Human Kidney using Mouse Anti-Human VHL Monoclonal Antibody (Catalog # MAB114351) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell surface in cells in convoluted tubules. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

VHL (von Hippel-Lindau disease tumor suppressor) is the substrate recognition subunit for an E3 ligase activity that ubiquitinates proteins containing hydroxyproline residues. Targets of VHL include HIF1α, β2 adrenergic receptor, ZHX2 and others. In VHL-box E3 Ubiquitin ligases, VHL is bound to a heterodimer complex composed of Elongin B (ELOB) and Elongin C (ELOC) through the "BC-box motif" found in many proteins in the VHL-box and SOCS-box protein families. ELOB/ELOC serves as an adapter between substrate recognition proteins and Cullin-2 (or Cullin-5) and RBX1 to form an active E3 ligase.

**References:**

1. Kamura T., *et al.* (1998) *Genes & Dev.* doi: 10.1101/gad.12.24.3872
2. Okumura F., *et al.* (2012) *Front. Oncol.* doi: 10.3389/fonc.2012.00010
3. Xie L., *et al.* (2009) *Sci. Signaling* doi: 10.1126/scisignal.2000444
4. Zhang J., *et al.* (2018) *Science* doi: 10.1126/science.aap8411